By Chloe Sheppard, Associate Consultant Contact: [email protected] A major milestone in the creation of pan-European joint health technology assessment (HTA) was reached in January this
By Fisentzos Stylianou, PhD Contact: [email protected] In November 2021, Novartis’ Adakveo (crizanlizumab) became the first treatment for sickle cell disease (SCD) to be made available
By Andrea Bernardini, Senior Analyst Email: [email protected] AIFA has approved reimbursement of the orphan drug Evrysdi (risdiplam) by Roche, the first at-home oral treatment for Spinal
By Andrea Bernardini, Senior Analyst Email: [email protected] Intensifying pressure to implement cost savings due to COVID induced economic downturn and the current ruling coalition, seem
By Andrea Bernardini, Senior Analyst Email: [email protected] The latest approved Budget Law for the three-year period 2022-2024 is quite extensive and covers the whole planned spending
By Richard Wang, Senior Analyst & Andrea Bernardini, Senior Analyst Email: [email protected] [email protected] On 10th of November, the Italian Medicines Agency AIFA announced that it
By Ciaran Cassidy, Snr Analyst Email: [email protected] On the 25th of July, the AEMPS of Spain published the first Therapeutic Positioning Report (Informe de Posicionamiento
By Max Rex, Consultant Email: [email protected] On Monday 7th June, the FDA approved aducanumab, the first new treatment for Alzheimer’s in 18 years. Aducanumab, manufactured
By Jayne Watson, Senior Analyst Email: [email protected] In April, the National Institute for Health and Care Excellence (NICE) launched its 5 year strategy, outlining their
